aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod for Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-Ild)

aTyr Pharma, Inc. announced that the US FDA has granted the company Fast Track designation for its lead therapeutic candidate, efzofitimod, for the treatment of SSc-Ild.